GPX Medical: Momentum in Clinical and Regulatory Activities Continues - Analyst Group

1.1 million infants die annually, where 80% suffer from Respiratory Distress Syndrome (RDS). The problem is extensive, and today there are no real sustainable solutions for monitoring RDS in real-time. GPX Medical AB (publ) (”GPX Medical” or “the Company”) develops the NEOLA®, which allows non-invasive, continuous monitoring of lung volume and oxygen changes in real-time. GPX Medical intends to initiate market launch during 2023, which is estimated to be followed by a rapid sales growth, with revenues reaching SEK 84m in 2026. Based on an applied P/S-multiple of 2.3x and a discount rate of 13%, this yields an equity value per share of SEK 5.0 in a Base scenario. Before market launch, we see several catalysts driving value, where steps in the right direction should reduce the current valuation discount.

Länk till analysen i sin helhet: https://www.analystgroup.se/analyser/gpx-medical-q1-22/